

[ Wed, Sep 25th 2024
] - WOPRAI

[ Mon, May 13th 2024
] - WOPRAI

[ Mon, Apr 01st 2024
] - WOPRAI

[ Wed, Mar 27th 2024
] - WOPRAI

[ Fri, Mar 01st 2024
] - WOPRAI

[ Tue, Jan 02nd 2024
] - WOPRAI

[ Fri, Dec 15th 2023
] - WOPRAI

[ Tue, Nov 14th 2023
] - WOPRAI

[ Fri, Aug 11th 2023
] - WOPRAI

[ Thu, May 25th 2023
] - WOPRAI

[ Mon, Mar 27th 2023
] - WOPRAI
[ Mon, Mar 27th 2023
] - WOPRAI
[ Mon, Mar 27th 2023
] - WOPRAI

[ Wed, Mar 01st 2023
] - WOPRAI

[ Wed, Jan 04th 2023
] - WOPRAI

[ Mon, Nov 14th 2022
] - WOPRAI

[ Tue, Mar 08th 2022
] - WOPRAI

[ Tue, Mar 01st 2022
] - WOPRAI

[ Tue, Aug 10th 2021
] - WOPRAI

[ Tue, Feb 16th 2021
] - WOPRAI

[ Tue, Feb 02nd 2021
] - WOPRAI

[ Mon, Dec 09th 2019
] - WOPRAI

Yanan Zhu Maintained (BLUE) at Hold with Decreased Target to $2 on, Sep 25th, 2024
Yanan Zhu of Wells Fargo, Maintained "bluebird bio, Inc." (BLUE) at Hold with Decreased Target from $3 to $2 on, Sep 25th, 2024.
Yanan has made no other calls on BLUE in the last 4 months.
There are 6 other peers that have a rating on BLUE. Out of the 6 peers that are also analyzing BLUE, 3 agree with Yanan's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Eric Schmidt of "Cantor Fitzgerald" Reiterated at Hold on, Monday, September 16th, 2024
- Luca Issi of "RBC Capital" Reiterated at Hold and Held Target at $4 on, Thursday, August 15th, 2024
- Eric Joseph of "JP Morgan" Downgraded from Buy to Hold on, Thursday, August 15th, 2024
These are the ratings of the 3 analyists that currently disagree with Yanan
- Gena Wang of "Barclays" Maintained at Buy with Decreased Target to $4 on, Thursday, August 15th, 2024
- Jack Allen of "Baird" Maintained at Buy with Decreased Target to $6 on, Thursday, August 15th, 2024
- Jason Gerberry of "B of A Securities" Maintained at Strong Buy with Decreased Target to $3 on, Thursday, August 15th, 2024